Tag Archives: Boehringer Ingelheim a

Boehringer Ingelheim and MiNA Therapeutics partner on the development of novel compounds to treat fibrotic liver diseases

Collaboration and licensing agreement focused on investigating up to three targets and has a potential transactional value of up to EUR 307 million, excluding royalties Expands Boehringer Ingelheim’s comprehensive R&D programme in non-alcoholic steatohepatitis (NASH) and fibrotic liver disease with … Read the full press release